[go: up one dir, main page]

NO328983B1 - Anvendelse av pegylert interferon alfa for fremstilling av et medikament for behandling av en pasient med renalt cellekarsinom. - Google Patents

Anvendelse av pegylert interferon alfa for fremstilling av et medikament for behandling av en pasient med renalt cellekarsinom. Download PDF

Info

Publication number
NO328983B1
NO328983B1 NO20014851A NO20014851A NO328983B1 NO 328983 B1 NO328983 B1 NO 328983B1 NO 20014851 A NO20014851 A NO 20014851A NO 20014851 A NO20014851 A NO 20014851A NO 328983 B1 NO328983 B1 NO 328983B1
Authority
NO
Norway
Prior art keywords
pegylated interferon
interferon alfa
patient
use according
treatment
Prior art date
Application number
NO20014851A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014851D0 (no
NO20014851L (no
Inventor
Mary Ellen Rybak
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20014851D0 publication Critical patent/NO20014851D0/no
Publication of NO20014851L publication Critical patent/NO20014851L/no
Publication of NO328983B1 publication Critical patent/NO328983B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20014851A 1999-04-08 2001-10-05 Anvendelse av pegylert interferon alfa for fremstilling av et medikament for behandling av en pasient med renalt cellekarsinom. NO328983B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08
PCT/US2000/009127 WO2000061174A2 (en) 1999-04-08 2000-04-06 Use of pegylated interferon alpha for renal cell carcinoma treatment

Publications (3)

Publication Number Publication Date
NO20014851D0 NO20014851D0 (no) 2001-10-05
NO20014851L NO20014851L (no) 2001-12-07
NO328983B1 true NO328983B1 (no) 2010-07-05

Family

ID=23106761

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014851A NO328983B1 (no) 1999-04-08 2001-10-05 Anvendelse av pegylert interferon alfa for fremstilling av et medikament for behandling av en pasient med renalt cellekarsinom.

Country Status (23)

Country Link
EP (2) EP1043025B1 (es)
JP (2) JP4721488B2 (es)
CN (1) CN1367702A (es)
AR (1) AR029160A1 (es)
AT (2) ATE296638T1 (es)
AU (2) AU777406B2 (es)
BR (1) BR0009644A (es)
CA (1) CA2303752A1 (es)
CO (1) CO5170412A1 (es)
CY (1) CY1108919T1 (es)
DE (2) DE60041291D1 (es)
DK (2) DK1535623T3 (es)
ES (2) ES2319777T3 (es)
HU (1) HU230271B1 (es)
MX (1) MXPA00003401A (es)
MY (1) MY155221A (es)
NO (1) NO328983B1 (es)
NZ (1) NZ514629A (es)
PE (1) PE20010026A1 (es)
PT (2) PT1043025E (es)
TW (2) TWI310314B (es)
WO (1) WO2000061174A2 (es)
ZA (1) ZA200108169B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4721488B2 (ja) * 1999-04-08 2011-07-13 シェーリング コーポレイション 腎細胞ガン処置
WO2007126950A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
KR20130001279A (ko) 2010-04-01 2013-01-03 온코레나 에이비 신장세포 암종의 향상된 치료
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
WO2024186735A1 (en) * 2023-03-03 2024-09-12 Memorial Sloan-Kettering Cancer Center Methods and compositions for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CZ302005B6 (cs) * 1998-03-26 2010-09-01 Schering Corporation Vodný prostredek PEG-interferon alfa konjugátu, jeho lyofilizát a výrobek jej obsahující
JP4721488B2 (ja) * 1999-04-08 2011-07-13 シェーリング コーポレイション 腎細胞ガン処置

Also Published As

Publication number Publication date
AU4204400A (en) 2000-11-14
EP1535623A1 (en) 2005-06-01
AU777406B2 (en) 2004-10-14
NO20014851D0 (no) 2001-10-05
TWI310314B (en) 2009-06-01
ES2319777T3 (es) 2009-05-12
DE60020442D1 (de) 2005-07-07
PE20010026A1 (es) 2001-02-05
EP1535623B1 (en) 2008-12-31
WO2000061174A3 (en) 2001-01-25
ZA200108169B (en) 2003-01-06
CY1108919T1 (el) 2014-07-02
EP1043025B1 (en) 2005-06-01
DE60041291D1 (de) 2009-02-12
HU230271B1 (hu) 2015-11-30
HUP0200781A3 (en) 2002-09-30
JP4721488B2 (ja) 2011-07-13
TW200526243A (en) 2005-08-16
NO20014851L (no) 2001-12-07
AR029160A1 (es) 2003-06-18
MY155221A (en) 2015-09-30
JP3712914B2 (ja) 2005-11-02
JP2001288110A (ja) 2001-10-16
ES2239953T3 (es) 2005-10-16
HK1032533A1 (en) 2001-07-27
DK1535623T3 (da) 2009-04-27
CA2303752A1 (en) 2000-10-08
CO5170412A1 (es) 2002-06-27
HUP0200781A2 (en) 2002-08-28
PT1043025E (pt) 2005-09-30
ATE419002T1 (de) 2009-01-15
AU2004242454A1 (en) 2005-01-20
WO2000061174A2 (en) 2000-10-19
HK1075417A1 (en) 2005-12-16
JP2000319196A (ja) 2000-11-21
NZ514629A (en) 2004-02-27
MXPA00003401A (es) 2002-03-08
CN1367702A (zh) 2002-09-04
DK1043025T3 (da) 2005-07-04
BR0009644A (pt) 2002-01-08
ATE296638T1 (de) 2005-06-15
DE60020442T2 (de) 2006-05-04
EP1043025A3 (en) 2000-12-20
PT1535623E (pt) 2009-03-19
EP1043025A2 (en) 2000-10-11
AU2004242454B2 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
US6685931B1 (en) Treatment of hepatitis C virus infections with interleukin-10
US7482014B2 (en) Melanoma therapy
NO328983B1 (no) Anvendelse av pegylert interferon alfa for fremstilling av et medikament for behandling av en pasient med renalt cellekarsinom.
US6362162B1 (en) CML Therapy
US6605273B2 (en) Renal cell carcinoma treatment
JP2001288110A6 (ja) 腎細胞ガン処置
AU2004242456B2 (en) CML therapy
NO328111B1 (no) Anvendelse av et pegylert interferon alfa-2b for fremstilling av et medikament for behandling av en pasient som har melanom som er blitt kirurgisk fjernet.
HK1075417B (en) Renal cell carcinoma treatment
HK1032533B (en) Renal cell carcinoma treatment
MXPA00003345A (es) Terapia para melanomas
HK1032349B (en) Melanoma therapy
HK1032348B (en) Chronic myeloid leukemia (cml) therapy
HK1075418A (en) Chronic myeloid leukemia (cml) therapy

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

MM1K Lapsed by not paying the annual fees